David Jayne
University of Cambridge
Internal medicineSurgeryPathologyDermatologyRandomized controlled trialIntensive care medicineRheumatologyImmunologyAnti-neutrophil cytoplasmic antibodyVasculitisCyclophosphamideSystemic vasculitisMicroscopic polyangiitisDiseaseRituximabGranulomatosis with polyangiitisANCA-Associated VasculitisClinical trialMedicineGastroenterology
423Publications
98H-index
30.7kCitations
Publications 416
Newest
#1Christopher Wall (UCLH: University College London Hospitals NHS Foundation Trust)
#1Christopher Wall (University of Cambridge)H-Index: 2
Last. Luigi Aloj (University of Cambridge)H-Index: 2
view all 27 authors...
Source
#1Alessandra Bettiol (UniFI: University of Florence)H-Index: 12
#2Maria Letizia Urban (UniFI: University of Florence)H-Index: 16
Last. Pavel Novikov (MSMU: I.M. Sechenov First Moscow State Medical University)H-Index: 12
view all 55 authors...
OBJECTIVE Mepolizumab proved efficacious for eosinophilic granulomatosis with polyangiitis (EGPA, former Churg-Strauss) at the dosage of 300mg/4 weeks in the randomized controlled MIRRA trial. Few successful real-life experiences with the dosage approved for severe eosinophilic asthma (100mg/4 weeks) were recently reported. We retrospectively assessed the effectiveness and safety of mepolizumab 100 and 300mg/4 weeks in a large European EGPA cohort. METHODS We included all EGPA patients treated w...
Source
#1Els Van de Perre (Vrije Universiteit Brussel)H-Index: 1
#2Rachel B Jones (University of Cambridge)H-Index: 22
Last. David Jayne (University of Cambridge)H-Index: 98
view all 3 authors...
Background The disease course of adult immunoglobulin A (IgA) vasculitis (IgAV; Henoch-Schonlein purpura) has not been well defined. Methods In a retrospective survey, we studied 85 adult IgAV patients with extended follow-up (median 43 months) for 67 patients. Results Only 33 of 67 (49%) achieved complete remission. Ongoing renal disease was the most common persistent organ manifestation, but extra-renal disease activity was also present in >50% of patients not achieving complete remission. Twe...
Source
#1Kaitlin A. Quinn (NIH: National Institutes of Health)H-Index: 7
#2Sara Monti (UNIPV: University of Pavia)H-Index: 28
Last. Peter Tugwell (U of O: University of Ottawa)H-Index: 151
view all 13 authors...
Abstract null null Objective null The Outcome Measures in Rheumatology (OMERACT) Vasculitis Working Group aims to develop composite response criteria for ANCA-Associated Vasculitis (AAV). null null null Methods null The project follows the OMERACT approach for composite measures: (i) choose relevant domains; (ii) define high-quality instruments; (iii) decide on a scoring system approach; (iv) put through the OMERACT Filter 2.1 for validation. null null null Results null A systematic literature r...
Source
#1K. Chavatza (UoA: National and Kapodistrian University of Athens)H-Index: 2
#2Myrto KostopoulouH-Index: 6
Last. Frédéric Houssiau (UCL: Université catholique de Louvain)H-Index: 66
view all 17 authors...
Background null Quality of care is receiving increased attention in systemic lupus erythematosus (SLE). We developed quality indicators (QIs) for SLE based on the 2019 update of European League Against Rheumatism recommendations. null Methods null A total of 44 candidate QIs corresponding to diagnosis, monitoring and treatment, were independently rated for validity and feasibility by 12 experts and analysed by a modified Research and Development Corporation/University of California Los Angeles m...
Source
Source
Source
Source
Source
Source